Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06147336 · ClinicalTrials.gov registry record · NA
A Multi-center, National, Open-label, Prospective Study to Evaluate the Performance of the V-Lap™ System
A NA study of Heart Failure, sponsored by Vectorious Medical Technologies.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06147336: Recruiting NA study of Heart Failure, sponsored by Vectorious Medical Technologies.
NCT06147336 is a NA study of Heart Failure that is actively recruiting participants, run by Vectorious Medical Technologies. The registered enrollment target is 10 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06147336, a NA study of Heart Failure, is actively recruiting participants, sponsored by Vectorious Medical Technologies.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the safety and performance of the V-LAP System in subjects with New York Heart Association (NYHA) functional class II and III HF, irrespective of left ventricular ejection fraction.
Primary Outcome
Freedom from failure of the V-LAP system to obtain LAP measurement from the sensor implant and transmit the LAP data to the V-LAPHCP HCP Interface and the V-LAPPSM Patient Guidance Application up to 12 months post-procedure.
Conditions Studied
Interventions
- DEVICE V-LAP™ SYSTEM
Study Locations (1)
Massachusetts
- One Boston Medical Center Place - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-06-11 |
| Est. Completion | 2028-04 |
| Phase | NA |
What NCT06147336 shows while recruiting
NCT06147336 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which V-LAP™ SYSTEM is the first listed.
NCT06147336 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06147336 about?
NCT06147336 is a clinical study titled "A Multi-center, National, Open-label, Prospective Study to Evaluate the Performance of the V-Lap™ System". The objective of this study is to evaluate the safety and performance of the V-LAP System in subjects with New York Heart Association (NYHA) functional class II and III HF, irrespective of left ventricular ejection fraction.
What is the current status of trial NCT06147336?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2024-06-11. Estimated completion is 2028-04.
What conditions does trial NCT06147336 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT06147336?
The interventions under investigation include: V-LAP™ SYSTEM (DEVICE).
Who is sponsoring clinical trial NCT06147336?
This trial is sponsored by Vectorious Medical Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06147336 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06147336's enrollment target sits among peer trials
10 383rd of 397 higher than 7 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI